THANK YOU...YOU'VE SAVED OUR SON'S LIFE
Daily Express|June 21, 2024
"This is fantastic news for anyone in the UK with this cruel condition...and for generations to come
Chris Riches
THANK YOU...YOU'VE SAVED OUR SON'S LIFE

A GRIM future for one-year-old Dexter Newton has become much brighter thanks to an Express campaign that has won him the right to receive a life-saving NHS drug.

Pressure from cystic fibrosis campaigners and a five-year.

Daily Express crusade have succeeded now anyone born with the condition will have access to wonder treatments which can prolong their lives.

The delighted parents of oneyear-old Dexter said he will "now have the chance of a full life not restricted by this genetic disease.

It's amazing." CF sufferer Carlie Pleasant, 34, who helped launch our campaign, said: "This is fantastic news for anyone in the UK who has this cruel condition and for the generations yet to come."

The life-limiting genetic condition slowly clogs the lungs with mucus. There are more than 11,000 sufferers in the UK, and there was no effective treatment on the NHS prior to 2019.

Our campaign began in February that year and by the October the first of three drugs from US pharma giant Vertex Orkambi, Symkevi and wonder pill Kaftrio - became available to UK patients.

They are currently used by some 8,000 CF patients. But last autumn NHS drug approver the National Institute for Health and Care Excellence (Nice) gave draft guidance that, despite transforming people's lives, they are too costly for new or future ČF patients to have.

The change would not have affected those already on treatment yet might have led to drugs being approved for current CF patients but denied to newborns.

Esta historia es de la edición June 21, 2024 de Daily Express.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

Esta historia es de la edición June 21, 2024 de Daily Express.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.